TL;DR — What You Need to Know
- 1.This study treated 42 GM patients primarily with lipophilic antibiotics (not steroids first), and saved steroids/surgery only for cases that didn't respond.
- 2.Corynebacterium bacteria were found in over half the patients — but standard lab cultures often miss them because they need special growth conditions.
- 3.Clarithromycin was the most-used antibiotic. The average treatment lasted 7 months, and the average time to clinical resolution was 8 months.
- 4.No patient in this series needed large-volume breast excision or mastectomy.
- 5.The authors suggest clinicians request specialized Corynebacterium cultures when evaluating GM tissue samples.
Why This Study Matters
Most women with Granulomatous Mastitis are told their condition is "idiopathic" — meaning the cause is unknown. Treatment approaches vary wildly: some doctors recommend watchful waiting, others prescribe steroids or methotrexate, and some push for surgery. This study offers a different perspective: what if GM is driven by bacteria that standard tests keep missing?
The research team at the University of Washington took a targeted approach. Instead of jumping to immunosuppressants, they focused on identifying infectious agents — particularly Corynebacterium species — and treating with antibiotics that can actually reach the bacteria inside breast tissue.
What They Did
The researchers reviewed the medical records of 42 patients with GM who were seen at their breast specialty clinic between 2004 and 2014. Their treatment strategy had five key components:
- Specialized lab requests: They asked microbiology labs to identifyCorynebacterium species at the species level (not just "diphtheroid contaminant").
- Lipophilic antibiotics: They chose antibiotics that penetrate fatty tissue well, since Corynebacterium lives inside lipid-filled spaces within granulomas.
- Prolonged treatment: They expected long courses because granulomas act like protective fortresses that shield bacteria from both the immune system and antibiotics.
- Steroids for refractory cases: Prednisone was used only when antibiotics alone weren't enough.
- Minimal surgery: Procedures were limited to drainage and small interventions — no mastectomies or large excisions.
What They Found
Bacteria Are More Common Than We Think
Bacteria were identified in 34 samples from 22 out of 42 patients (52.3%). The most common finding was "diphtheroids" (presumptive Corynebacterium species), followed by confirmed Corynebacterium species and Propionibacterium acnes (now called Cutibacterium acnes).
Here's the critical point: standard cultures often miss these bacteria. C. kroppenstedtii — the species most linked to GM — needs lipid supplementation (like Tween 80) and longer incubation times to grow. On regular culture plates, it might not grow at all, or it might be dismissed as a harmless skin contaminant.
Antibiotics as First-Line Treatment
Antibiotics were the preferred first-line medical therapy, used in 33 out of 36 patients (91.7%) who received medical treatment.Clarithromycin was the antibiotic of choice and was the initial antibiotic in 15 of the 33 patients (45.5%).
The average duration of antibiotic therapy was 7.0 ± 4.5 months. Eleven patients needed adjunctive prednisone, with an average steroid course of 4.3 ± 2.5 months.
Surgery Was Minimal
When surgery was needed, it was conservative: incision and drainage in 7 patients, fine needle aspiration in 8 patients, and excision of a fistulous tract in 1 patient. No patients underwent large-volume excision or mastectomy.
Time to Resolution
The average time from the first breast clinic visit to clinical resolution was 8.0 ± 4.6 months. This tells us that even with targeted therapy, GM takes time to resolve — patience and persistence are part of the process.
What This Means for Patients
Ask about special cultures
If your tissue or fluid samples came back negative, ask your doctor whether the lab looked specifically for Corynebacterium species with appropriate media and extended incubation. Standard cultures aren't designed to find these slow-growing bacteria.
Lipophilic antibiotics may be worth discussing
Clarithromycin and other lipophilic antibiotics can penetrate fatty breast tissue where standard antibiotics (like penicillins and cephalosporins) may not reach effectively. This is worth bringing up with your physician, especially if short antibiotic courses haven't worked.
Expect a longer timeline
The average resolution time in this study was 8 months. If you're on month 3 or 4 and still have symptoms, that doesn't necessarily mean treatment is failing — it may just mean your body needs more time.
Surgery isn't always necessary
In this series, no one needed mastectomy or large excision. Conservative procedures like drainage were sufficient when needed. This supports the idea that medical management should be tried before considering aggressive surgery.
Important Caveats
- This was a retrospective case series, not a randomized controlled trial. That means there's no comparison group, and we can't definitively say this approach is better than steroids or observation.
- The study was conducted at a single institution with a specific treatment philosophy. Results may not apply everywhere.
- Not all patients had bacteria identified — nearly half didn't. This suggests GM may have multiple causes, and antibiotics won't help everyone.
- Always work with a qualified physician. This article is educational, not medical advice.
The Bottom Line
This study adds important evidence that GM may be an infectious disease driven by bacteria like Corynebacterium kroppenstedtii, and that prolonged lipophilic antibiotic therapy — particularly clarithromycin — can be an effective treatment with low morbidity. It challenges the "idiopathic" label and suggests that better lab testing and targeted antibiotic selection could change outcomes for many women.
If you're currently navigating GM treatment, this paper is worth bringing to your physician as a conversation starter — especially if you're considering your options or if standard treatments haven't worked.
Read the full research paper
Download the original 2021 publication by Williams et al. from the European Journal of Breast Health to review the complete data, methods, and discussion with your care team.
Download PDF